The import of antisera and other blood fractions to Canada exhibits a steady growth trajectory from 2024 through 2028, with values increasing from USD 3.72 billion in 2024 to USD 4.17 billion in 2028. On a year-over-year basis, the imports are projected to grow by approximately 3.11% to 3.41% annually. This indicates a continued demand in Canada's healthcare sector post-2023, a year whose actual import values provide the baseline. Analyzing over this five-year period reveals a compound annual growth rate (CAGR) of approximately 2.87%, highlighting consistent expansion.
Future trends to watch include potential impacts from innovation in biotechnology, changes in healthcare policies, and global supply chain dynamics. These factors might influence the demand and supply balance and potentially alter import growth rates. Monitoring regulatory developments and technological advancements will be crucial for forecasting beyond 2028.
